Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

The osteoarthritis market is projected to grow from 2026 to 2036, driven by an aging population and rising disease prevalence. The expected launch of emerging therapies such as LEVI-04 (Levicept), ZILOSUL (Paradigm Biopharmaceuticals), TissueGene-C (TG-C) (Kolon TissueGene), AMZ001 (Amzell), SAR446959 (Sanofi), PCRX-201 (enekinragene inzadenovec) (Pacira BioSciences), and others is further supporting market expansion.

The osteoarthritis market is projected to grow from 2026 to 2036, driven by an aging population and rising disease prevalence. The expected launch of emerging therapies such as LEVI-04 (Levicept), ZILOSUL (Paradigm Biopharmaceuticals), TissueGene-C (TG-C) (Kolon TissueGene), AMZ001 (Amzell), SAR446959 (Sanofi), PCRX-201 (enekinragene inzadenovec) (Pacira BioSciences), and others is further supporting market expansion.